20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Atea Pharmaceuticals Inc (AVIR) operates in the BIOTECHNOLOGY industry and is headquartered in Boston, United States with about 55 employees. Its market capitalization is roughly $330 million. In the fiscal year ended 2025-12-31, AVIR reported $0M in revenue and ($158M) in net income.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $192M | $351M | $49M | $0M | $0M |
| Gross Profit | — | $0M | ($83M) | ($70M) | $0M | $351M | $11M | $0M | $0M |
| Gross Margin % | — | — | — | — | -0.1% | 100.0% | 21.8% | — | — |
| Operating Income (EBIT) | ($184M) | ($181M) | ($193M) | ($164M) | ($131M) | $138M | ($11M) | ($15M) | ($9M) |
| Operating Margin % | — | — | — | — | -68.0% | 39.4% | -22.7% | — | — |
| Net Income | ($165M) | ($158M) | ($168M) | ($136M) | ($116M) | $121M | ($11M) | ($13M) | ($9M) |
| Net Margin % | — | — | — | — | -60.3% | 34.5% | -22.5% | — | — |
| EBITDA | ($171M) | ($164M) | ($132M) | ($120M) | ($130M) | $138M | ($11M) | ($15M) | ($9M) |
| Earnings Per Share (EPS) | $-2.09 | $-1.94 | $-2.00 | $-1.63 | $-1.39 | $1.37 | $-0.13 | $-0.16 | $-0.90 |
| Shares Outstanding (M) | 80M | 81M | 84M | 83M | 83M | 88M | 82M | 83M | 10M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Gross Profit | — | $0M | $0M | ($38M) | ($2M) | ($3M) | $0M | ($20M) |
| Gross Margin % | — | — | — | — | — | — | -25.0% | — |
| Operating Income (EBIT) | ($35M) | ($48M) | ($55M) | ($46M) | ($41M) | ($39M) | ($39M) | ($37M) |
| Operating Margin % | — | — | — | — | — | — | -9381.2% | — |
| Net Income | ($33M) | ($45M) | ($45M) | ($42M) | ($37M) | ($34M) | ($34M) | ($31M) |
| Net Margin % | — | — | — | — | — | — | -8063.2% | — |
| EBITDA | ($33M) | ($45M) | ($52M) | ($42M) | ($41M) | ($34M) | ($33M) | ($31M) |
| Earnings Per Share (EPS) | $-0.41 | $-0.57 | $-0.57 | $-0.53 | $-0.44 | $-0.40 | $-0.40 | $-0.37 |
| Shares Outstanding (M) | 80M | 79M | 78M | 79M | 84M | 85M | 84M | 84M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($152M) | ($132M) | ($135M) | ($85M) | ($121M) | ($87M) | $297M | ($13M) | ($8M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $2M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($152M) | ($132M) | ($135M) | ($85M) | ($123M) | ($87M) | $297M | ($13M) | ($8M) |
| FCF Margin % | — | — | — | — | -64.0% | -24.8% | 610.1% | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($37M) | ($46M) | ($28M) | ($40M) | ($33M) | ($31M) | ($30M) | ($23M) |
| Free Cash Flow (FCF) | ($37M) | ($46M) | ($28M) | ($40M) | ($33M) | ($31M) | ($30M) | ($23M) |
| FCF Margin % | — | — | — | — | — | — | -7307.0% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $232M | $315M | $465M | $595M | $667M | $773M | $864M | $22M | $35M |
| Cash & Cash Equivalents | $77M | $96M | $65M | $144M | $647M | $764M | $850M | $22M | $34M |
| Total Liabilities | $28M | $40M | $26M | $40M | $26M | $63M | $316M | $72M | $71M |
| Total Debt (Short + Long-Term) | $0M | $1M | $1M | $1M | $1M | $0M | $0M | $0M | $0M |
| Total Shareholders' Equity | $204M | $275M | $439M | $555M | $641M | $710M | $548M | ($50M) | ($36M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AVIR viewer.
About TickerBase · Data methodology & sources · Privacy · Terms